Tiny paclitaxel particles aim to hit tumors harder

NCT ID NCT03537690

Ongoing Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into tumors while sparing healthy cells. The main goals are to find the safest dose and to watch for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FID-007 (a nano-encapsulated form of the chemotherapy drug paclitaxel)
What this could lead to: If it works, this could provide a new treatment option for people with advanced solid tumors that no longer respond to standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 50 participants, so the main goal is safety, not effectiveness. The drug may still cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID NEOPLASM REFRACTORY MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

Hoag Memorial Hospital

Newport Beach, California, 92663, United States
Los Angeles General Medical Center

Los Angeles, California, 90033, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.